Anticancer Res

1. RADES D, Cremers F, Ziemann C, Splettstosser L, et al
   Changes in Bladder Volume During Radiotherapy for Prostate Cancer.
   Anticancer Res. 2024;44:4457-4463.
   

   >> Share

   
   
2. POULSEN TS, Lorup AN, Kongsted P, Eefsen RL, et al
   TMPRSS2:ERG Gene Fusion Might Predict Resistance to PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer.
   Anticancer Res. 2024;44:4203-4211.
   

   >> Share

   
   

   
   BMC Urol

3. PERRY AG, Kahn A, Mercuri J, Rini K, et al
   Preclinical and clinical evidence for using perinatal tissue allografts in nerve sparing robot assisted radical prostatectomy to hasten recovery of functional outcomes: a literature review.
   BMC Urol. 2024;24:208.
   

   >> Share

   
   
4. OSHIMA M, Washino S, Yazaki K, Mayumi S, et al
   Impact of oral antithrombotic agents on urinary continence recovery following robot-assisted radical prostatectomy: a retrospective cohort study.
   BMC Urol. 2024;24:211.
   

   >> Share

   
   
5. ZHU Z, Zhu Y, Zhou Y, Zhou P, et al
   Importance of biopsy sample length for cancer diagnosis during trans-perineal prostate biopsy.
   BMC Urol. 2024;24:209.
   

   >> Share

   
   

   
   Int J Radiat Oncol Biol Phys

6. WISDOM AJ, Yeap BY, Michalski JM, Horick NK, et al
   Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy vs. IMRT for Localized Prostate Cancer.
   Int J Radiat Oncol Biol Phys. 2024 Sep 26:S0360-3016(24)03444.
   

   >> Share

   
   
7. MORGAN KM, Deshler LN, Tibbs MD, Qiao EM, et al
   Prostate Specific Antigen and Prostate Cancer in Gender Affirming Hormone Therapy for Transgender or Nonbinary Individuals.
   Int J Radiat Oncol Biol Phys. 2024 Sep 25:S0360-3016(24)03409.
   

   >> Share

   
   

   
   Int J Urol

8. YANAI Y, Mikami S, Yasumizu Y, Takeda T, et al
   Loss of phosphatase and tensin homolog expression castration-sensitive prostate cancer predicts outcomes in men after prostatectomy.
   Int J Urol. 2024 Oct 1. doi: 10.1111/iju.15592.
   

   >> Share

   
   
9. KOHADA Y, Kitano H, Tasaka R, Miyamoto S, et al
   Clinical characteristics and predictors of long-term postoperative urinary incontinence in patients treated with robot-assisted radical prostatectomy: A propensity-matched analysis.
   Int J Urol. 2024;31:1145-1152.
   

   >> Share

   
   

   
   J Clin Oncol

10. BROOKS JD
    Stockholm3 in a Multiethnic Cohort: Optimizing Prostate Cancer Screening to Reduce Harm and Improve Equity.
    J Clin Oncol. 2024 Oct 3:JCO2400941. doi: 10.1200/JCO.24.00941.
    

    >> Share

    
    

    
    J Natl Cancer Inst

11. COOPERBERG MR, Braun AE, Berlin A, Kibel AS, et al
    When is prostate cancer really cancer?
    J Natl Cancer Inst. 2024 Oct 1:djae200. doi: 10.1093.
    

    >> Share

    
    

    
    J Nucl Med

12. PISANO G, van Oosterom MN, Berrens AC, Slof LJ, et al
    Freehand SPECT Combined with 3-Dimensional Light Detection and Ranging as Alternative Means of Specimen Scanning During Prostate Cancer Surgery.
    J Nucl Med. 2024 Oct 3:jnumed.124.268256. doi: 10.2967/jnumed.124.268256.
    

    >> Share

    
    

    
    J Urol

13. STONE BV, Dominas CA, Bhagavatula SK, Ahn SW, et al
    Novel intraprostatic MR-guided implantation of multidrug-eluting microdevice for testing of systemic therapy agents in situ; Proof of concept in intermediate- and high-risk prostate cancer.
    J Urol. 2024 Sep 30:101097JU0000000000004269. doi: 10.1097/JU.0000000000004269.
    

    >> Share

    
    
14. BHANJI Y, Mamawala MK, Fletcher SA, Landis P, et al
    Is Confirmatory Biopsy Still Necessary for Active Surveillance of Men With Grade Group 1 Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging?
    J Urol. 2024 Oct 2:101097JU0000000000004268. doi: 10.1097/JU.0000000000004268.
    

    >> Share

    
    
15. FLORES JM, Vertosick EA, Salter CA, Benfante N, et al
    Testosterone Therapy in Men After Radical Prostatectomy for Organ-Confined, Low-Intermediate Prostate Cancer.
    J Urol. 2024 Sep 30:101097JU0000000000004267. doi: 10.1097/JU.0000000000004267.
    

    >> Share

    
    

    
    Lancet Oncol

16. JIA AY, Spratt DE
    A step closer to the use of [(177)Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer.
    Lancet Oncol. 2024;25:1246-1247.
    

    >> Share

    
    

    
    PLoS One

17. O'DONNELL A, Cronin M, Moghaddam S, Wolsztynski E, et al
    Pre-operative prediction of BCR-free survival with mRNA variables in prostate cancer.
    PLoS One. 2024;19:e0311162.
    

    >> Share

    
    

    
    Prostate

18. DINCKAL M, Ergun KE, Kalemci MS, Guler E, et al
    Head-to-head comparison of GA-68 PSMA PET/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer.
    Prostate. 2024 Sep 30. doi: 10.1002/pros.24799.
    

    >> Share

    
    
19. NARITA S, Yanagisawa T, Hatakeyama S, Hata K, et al
    Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy.
    Prostate. 2024 Sep 30. doi: 10.1002/pros.24802.
    

    >> Share

    
    
20. YAZGAN SC, Yekeduz E, Araz M, Bolek H, et al
    The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 ((177)Lu)-PSMA-617.
    Prostate. 2024 Sep 29. doi: 10.1002/pros.24804.
    

    >> Share

    
    

    
    Urol Int

21. OPPOLZER IA, Schnabel MJ, Hammer S, Zilles H, et al
    Impact of SARS-CoV-2-Pandemic on diagnosis of prostate cancer.
    Urol Int. 2024 Oct 3:1-15. doi: 10.1159/000541753.
    

    >> Share

    
    
22. BULBUL O, Nak D, Goksel S
    Prediction of lesion-based treatment response after two cycles of Lu-177 PSMA treatment in metastatic castration-resistant prostate cancer using machine learning.
    Urol Int. 2024 Sep 30:1-12. doi: 10.1159/000541628.
    

    >> Share

    
    

    
    Urology

23. BOWLING GC, Albright JA, Maloney TJ, Chesnut GT, et al
    Reply to Editorial Comment on "Poor Bone Mineral Density is Associated With Increased Risk of Urological Metastases".
    Urology. 2024;192:98-99.
    

    >> Share

    
    
24. SINGLA N
    Editorial Comment on "Poor Bone Mineral Density is Associated With Increased Risk of Urological Bone Metastases".
    Urology. 2024;192:97-98.
    

    >> Share

    
    
25. SOPUTRO NA, Olivares R
    Editorial Comment on "Impact of Preoperative LUTS on Health-related Quality of Life Following Radical Prostatectomy: A Propensity Score Matched Longitudinal Study".
    Urology. 2024;192:59-60.
    

    >> Share

    
    
26. BOWLING GC, Alex Albright J, Maloney TJ, Quinn MS, et al
    Poor Bone Mineral Density Is Associated With Increased Risk of Urological Bone Metastases.
    Urology. 2024;192:88-96.
    

    >> Share

    
    
27. WESTHOFEN T, Feyerabend E, Buchner A, Schlenker B, et al
    Impact of Preoperative LUTS on Health-related Quality of Life Following Radical Prostatectomy: A Propensity Score Matched Longitudinal Study.
    Urology. 2024;192:52-58.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share